论文部分内容阅读
目的:探讨复方蜥蜴散不同微粒组合剂(简称XY)创新模式(独特配方、不同微粒、糊剂给药)抗癌、阻癌及抑癌的分子生物学机制。方法:将120只SPF级SD大鼠随机抽取20只作为空白对照组,其余100只采用0.02 mol·L-1的甲基硝基亚硝基胍(MNNG)溶液按5 mL·kg-1灌胃等综合因素造模8周,成功制备胃癌前病变(precancerous leisions of gastric cancer,PLGC)大鼠模型后随机分为模型对照组、复方蜥蜴散80目组、100目组、80目100目等量混合组(XY80组、XY100组、XY80+100组均为1.5 g·kg-1·d-1)、维酶素组(0.3 g·kg-1·d-1)共5组,每组13只,均作相应处理后应用免疫组化法检测其对B淋巴细胞瘤/白血病-2(B-cell lymphoma/leuke-2基因,Bcl-2)和生存素(survivin)表达的影响。结果:各组大鼠胃黏膜组织Bcl-2和survivin的平均吸光度(A):空白对照组(19.06±2.32/21.46±2.69)、模型对照组(30.20±4.83/29.29±3.51)、XY80组(22.14±3.57/24.18±2.82)、XY100组(21.98±3.06/24.05±2.80)、XY80+100组(19.15±2.67/21.63±2.61)、维酶素组(24.80±2.89/26.59±3.36),经统计学分析,模型对照组与空白对照组比较,差异有统计学意义(P<0.05),各治疗组与模型对照组比较,差异有统计学意义(P<0.05),XY各治疗组与维酶素组比较,差异有统计学意义(P<0.05),尤以XY80+100组A最低,XY80组、XY100组与XY80+100组比较,差异有统计学意义(P<0.05);经Pearson相关分析,survivin与Bcl-2表达呈正相关(P<0.05),相关系数(r)=0.935。结论:Bcl-2和survivin在PLGC过程中具有协同作用;复方蜥蜴散不同微粒组合剂创新模式不仅配方独特,而且采用80目和100目等量混合和糊剂给药方式可进一步下调凋亡抑制基因Bcl-2和Survivin的表达,从而实现有效干预PLGC和延缓癌变进程的作用。
OBJECTIVE: To investigate the molecular mechanism of anti-cancer, anti-cancer and anti-cancer in the innovative model (special formula, different particles and paste administration) of different compounds of Lizards Powder (XY). Methods: Totally 120 Sprague-Dawley (SD) SD rats were randomly selected as the blank control group. The other 100 animals were treated with 0.02 mmol·L-1 MNNG solution (5 mL · kg -1) Stomach and other comprehensive factors for 8 weeks, the successful preparation of gastric precancerous lesions (precancerous leisions of gastric cancer, PLGC rat model were randomly divided into model control group, compound lizards scattered 80 mesh group, 100 mesh group, 80 mesh 100 mesh (1.5 g · kg-1 · d-1 in XY80 group, XY100 group, XY80 + 100 group) and 5 μg · kg-1 · d-1 Thirteen of them were all treated with Bcl-2, Bcl-2 and Survivin. The expression of Bcl-2, Bcl-2 and survivin were detected by immunohistochemistry. RESULTS: The average absorbance of Bcl-2 and survivin in gastric mucosa of rats in each group was (19.06 ± 2.32 / 21.46 ± 2.69), that in model control group (30.20 ± 4.83 / 29.29 ± 3.51) and XY80 group 22.14 ± 3.57 / 24.18 ± 2.82), XY100 group (21.98 ± 3.06 / 24.05 ± 2.80), XY80 + 100 group (19.15 ± 2.67 / 21.63 ± 2.61), Vetiver group (24.80 ± 2.89 / 26.59 ± 3.36) Statistical analysis, the model control group and the blank control group, the difference was statistically significant (P <0.05), the treatment group compared with the model control group, the difference was statistically significant (P <0.05), XY each treatment group and dimension Compared with XY80 + 100 group, the difference was statistically significant (P <0.05), especially in XY80 + 100 group, XY80 + XY100 + group, the difference was statistically significant (P <0.05) Correlation analysis showed that there was a positive correlation between the expression of survivin and Bcl-2 (P <0.05), and the correlation coefficient (r) was 0.935. Conclusion: Bcl-2 and survivin have a synergistic effect in the process of PLGC. The innovative model of compound lizards powder particles not only has a unique formula, but also inhibits the apoptosis by using the mixed dosage of 80 mesh and 100 mesh and paste Gene Bcl-2 and Survivin expression, in order to achieve effective intervention in PLGC and delay the role of cancer progression.